Breaking News

Esphera SynBio Launches Project to Enhance mRNA Vaccines

Will leverage its proprietary technology to engineer mRNA vaccines that, upon delivery, instruct patient cells to produce modified nanomedicines.

Author Image

By: Charlie Sternberg

Associate Editor

Esphera SynBio, a pre-clinical stage synthetic biology company, has launched a new project aimed at enhancing the efficacy of mRNA vaccines. The company will leverage its proprietary technology to engineer mRNA vaccines that, upon delivery, instruct patient cells to produce modified nanomedicines. These in situ-produced nanomedicines are designed to have precise targeting capabilities and tailored immunostimulatory payloads, potentially overcoming limitations of current mRNA vaccine platforms...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics